In Re: Fosamax Products Liability Litigation

Track this case

Case overview

Case Number:

1:06-md-01789

Court:

New York Southern

Nature of Suit:

365 Personal Inj. Prod. Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

John F. Keenan

Firms

Companies

Sectors & Industries:

December 19, 2013
Generic Fosamax Users Must Give More Details In MDL

A New York federal judge on Wednesday ordered plaintiffs in multidistrict litigation against Teva Pharmaceuticals USA Inc. to divulge when they had taken a generic version of the bone drug Fosamax, in order to back the claim that Teva's failure to update the drug's labeling had led to their jaw injuries.
December 09, 2013
Merck Settles Fosamax Jaw-Injury Claims For $28M

Resolving long-running multidistrict litigation in New York, Merck & Co. Inc. agreed Monday to pay $27.7 million to settle hundreds of lawsuits claiming its bone drug Fosamax caused a condition known as osteonecrosis of the jaw.
October 02, 2013
Merck Opposes Delay In Wind-Down Of Fosamax MDL

In a turnaround Friday, Merck & Co. Inc. urged a New York federal judge to stick to the planned wind-down of multidistrict litigation over jaw injuries allegedly caused by the bone drug Fosamax, after plaintiffs asked for a stay in the transfer of cases.
August 30, 2013
Fosamax MDL To Wind Down More Swiftly Than Merck Wanted

A New York federal judge decided Thursday to transfer cases out of the Fosamax jaw injury multidistrict litigation against Merck & Co. Inc. at an even faster pace than proposed by the plaintiffs, who have pushed strongly for a speedy transition.
August 22, 2013
Merck Can't Force Fosamax Plaintiffs To Verify Injuries

A New York federal judge on Thursday refused to force hundreds of alleged victims of Merck & Co.'s bone drug Fosamax to substantiate their injuries or else face dismissal from multidistrict litigation over the drug, saying the process would devolve into a fight on the merits of each case.
August 19, 2013
Merck, Plaintiffs Bicker Over Fosamax MDL Wind-Down Plans

Merck & Co. Inc. and the plaintiffs suing the company over jaw injuries allegedly caused by the bone drug Fosamax proposed competing plans for the wind-down of multidistrict litigation on Monday, with the drugmaker claiming its opponents seek to "dump" the cases across the country.
August 15, 2013
Labeling Update Claims Survive Dismissal In Fosamax MDL

A New York federal judge ruled Thursday that manufacturers of generic versions of the bone drug Fosamax can be held liable for failing to match their warning labels to the brand-name label, in multidistrict litigation over a jaw condition allegedly caused by the drug.
August 15, 2013
Merck, Plaintiffs Fail To Reach Deal In Fosamax Jaw MDL

Merck & Co. Inc. and a group of plaintiffs in multidistrict litigation over jaw injuries allegedly caused by the bone drug Fosamax broke off settlement talks on Wednesday, a day after a judge peppered the drugmaker with questions about why it has not yet resolved the litigation.
August 12, 2013
Merck Wants Fosamax Plaintiffs To Cough Up Evidence

Merck & Co. on Monday asked the federal judge handling multidistrict litigation over the safety of its bone drug Fosamax to force some plaintiffs to substantiate their claims, a move that could see hundreds of cases cut from the MDL.
July 01, 2013
Merck Can't Duck Jury Award In Fosamax Bellwether Suit

A New York federal judge on Monday denied Merck & Co. Inc.'s attempt to wipe out a $285,000 plaintiff verdict in a bellwether trial in multidistrict litigation claiming the bone drug Fosamax causes jaw deterioration, rejecting its argument that its warning was adequate.

← Previous
1
2
Next →